BACKGROUND: Dedifferentiated chondrosarcoma (DDC) accounts for a small proportion of chondrosarcomas. They demonstrate aggressive behaviour with a high rate of local recurrence and systemic progression resulting in poor long-term survival rates. Due to its relatively low incidence, previous studies have grouped different histiotypes together to achieve adequate study numbers for analysis. METHODS: This retrospective study examines the clinical course and the role of chemotherapy in the subgroup of patients with DDC where osteosarcoma is the predominant dedifferentiated component. Between 2000-2010, 21 patients were identified. RESULTS: The mean age at presentation was 64 years (range 35-80 years). 12 patients were considered unfit for chemotherapy, whilst 2 patients declined chemotherapy. 5 patients received neoadjuvant chemotherapy, with less than 90% necrosis demonstrated in all these cases. 3 patients received post-operative chemotherapy. The median survival for the entire group was 9.5 months. In the 7 patients who received chemotherapy, the median survival was 17 months, and those who had chemotherapy had a greater median time to local recurrence. CONCLUSION: This study demonstrates that cytotoxic chemotherapy may be offered to appropriately selected patients.
BACKGROUND: Dedifferentiated chondrosarcoma (DDC) accounts for a small proportion of chondrosarcomas. They demonstrate aggressive behaviour with a high rate of local recurrence and systemic progression resulting in poor long-term survival rates. Due to its relatively low incidence, previous studies have grouped different histiotypes together to achieve adequate study numbers for analysis. METHODS: This retrospective study examines the clinical course and the role of chemotherapy in the subgroup of patients with DDC where osteosarcoma is the predominant dedifferentiated component. Between 2000-2010, 21 patients were identified. RESULTS: The mean age at presentation was 64 years (range 35-80 years). 12 patients were considered unfit for chemotherapy, whilst 2 patients declined chemotherapy. 5 patients received neoadjuvant chemotherapy, with less than 90% necrosis demonstrated in all these cases. 3 patients received post-operative chemotherapy. The median survival for the entire group was 9.5 months. In the 7 patients who received chemotherapy, the median survival was 17 months, and those who had chemotherapy had a greater median time to local recurrence. CONCLUSION: This study demonstrates that cytotoxic chemotherapy may be offered to appropriately selected patients.
Authors: Charles A Gusho; Linus Lee; Athan Zavras; Zachary Seikel; Ira Miller; Matthew W Colman; Steven Gitelis; Alan T Blank Journal: Orthop Rev (Pavia) Date: 2022-05-31
Authors: Lee D Cranmer; Bonny Chau; Jose G Mantilla; Elizabeth T Loggers; Seth M Pollack; Teresa S Kim; Edward Y Kim; Gabrielle M Kane; Matthew J Thompson; Jared L Harwood; Michael J Wagner Journal: Clin Orthop Relat Res Date: 2022-04-01 Impact factor: 4.755
Authors: Ruoyu Miao; Edwin Choy; Kevin A Raskin; Joseph H Schwab; Gunnlaugur Petur Nielsen; Vikram Deshpande; Ivan Chebib; Thomas F DeLaney; Francis J Hornicek; Gregory M Cote; Yen-Lin E Chen Journal: Sarcoma Date: 2019-12-13
Authors: Agnieszka E Zając; Sylwia Kopeć; Bartłomiej Szostakowski; Mateusz J Spałek; Michał Fiedorowicz; Elżbieta Bylina; Paulina Filipowicz; Anna Szumera-Ciećkiewicz; Andrzej Tysarowski; Anna M Czarnecka; Piotr Rutkowski Journal: Cancers (Basel) Date: 2021-05-14 Impact factor: 6.639